Kura Oncology (NASDAQ:KURA) Rating Reiterated by Wedbush

Kura Oncology (NASDAQ:KURA)‘s stock had its “outperform” rating reissued by Wedbush in a note issued to investors on Friday, Benzinga reports. They currently have a $37.00 price target on the stock. Wedbush’s price target would suggest a potential upside of 79.35% from the stock’s previous close.

Several other equities analysts have also recently weighed in on KURA. HC Wainwright reaffirmed a “buy” rating and set a $32.00 target price on shares of Kura Oncology in a research note on Monday, April 22nd. JMP Securities lifted their target price on Kura Oncology from $22.00 to $32.00 and gave the company a “market outperform” rating in a research note on Wednesday, January 31st. Finally, StockNews.com cut Kura Oncology from a “hold” rating to a “sell” rating in a research note on Monday, April 15th. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $28.28.

Kura Oncology Trading Up 0.2 %

Shares of KURA opened at $20.63 on Friday. The business’s 50-day moving average price is $20.66 and its 200 day moving average price is $15.99. The stock has a market capitalization of $1.57 billion, a P/E ratio of -9.51 and a beta of 0.89. Kura Oncology has a 1-year low of $7.41 and a 1-year high of $24.17. The company has a current ratio of 12.26, a quick ratio of 12.26 and a debt-to-equity ratio of 0.02.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Thursday, May 2nd. The company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.03). The company’s quarterly revenue was up .0% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.50) earnings per share. Analysts expect that Kura Oncology will post -2.35 earnings per share for the current year.

Institutional Investors Weigh In On Kura Oncology

Several institutional investors have recently made changes to their positions in the company. BVF Inc. IL lifted its holdings in shares of Kura Oncology by 9.5% during the 4th quarter. BVF Inc. IL now owns 7,373,228 shares of the company’s stock valued at $106,027,000 after buying an additional 642,245 shares during the last quarter. Deerfield Management Company L.P. Series C lifted its holdings in Kura Oncology by 35.1% in the 3rd quarter. Deerfield Management Company L.P. Series C now owns 4,374,044 shares of the company’s stock worth $39,891,000 after purchasing an additional 1,136,044 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Kura Oncology by 7.5% in the 3rd quarter. Vanguard Group Inc. now owns 3,924,448 shares of the company’s stock worth $35,791,000 after purchasing an additional 275,173 shares during the last quarter. Armistice Capital LLC lifted its holdings in Kura Oncology by 5.3% in the 3rd quarter. Armistice Capital LLC now owns 2,236,000 shares of the company’s stock worth $20,392,000 after purchasing an additional 112,000 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in Kura Oncology by 10.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,001,754 shares of the company’s stock worth $28,785,000 after purchasing an additional 197,530 shares during the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.